47 research outputs found
Investigating the risks of morbidity and mortality in patients with diabetes in Hungary
Világszerte több mint félmilliárd ember szenved cukorbetegségben és
előfordulása növekvő tendenciát mutat, ezért népegészségügyi szempontból
nagy jelentőséggel bír.
A cukorbetegség két leggyakoribb formája az 1-es és a 2-es típusú
cukorbetegség, melyek eltérnek a kardiovaszkuláris szövődmények, valamint
a daganatok, a hipoglikémia és a diabéteszes ketoacidózis kialakulásának
gyakorisága szempontjából.
Kutatásom egyik fő iránya ennek a két gyakori, de eltérő típusú
cukorbetegségben előforduló szövődmények vizsgálata, továbbá az 1-es és a
2-es típusú fiatal diabéteszes páciensek megbetegedési és halálozási
kockázatainak elemzése.
A diabétesz prevalenciájának emelkedése mellett gyorsan nő a daganatos
megbetegedések előfordulása és halálozása világszerte. Az utóbbi években
megjelent tanulmányok szerint a kardiovaszkuláris betegségek mellett a
daganatos betegségek váltak a vezető halálokokká a cukorbetegek körében,
ez a trend pedig a cukorbetegség és az antidiabetikus szerek daganatra
kifejtett hatásának vizsgálatát helyezi a tudományos kutatások
középpontjába.
Kutatásom másik fő iránya a nátrium-glükóz-kotranszporter 2 gátló (SGLT2i),
valamint dipeptidil-peptidáz-4 gátló (DPP-4i) kezelésben részesült 2-es típusú
diabéteszes betegpopulációkban a különböző daganat típusok kialakulási
kockázatának elemzése
A cukorbeteg-ellátás mutatóinak alakulása Magyarországon 2001–2014 között. Az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének célja és módszertana | Changes in features of diabetes care in Hungary in the period of years 2001–2014
Absztrakt
Napjainkban a cukorbetegséggel kapcsolatos adatbázis-elemzések új lehetőségként
vonultak be a klinikai kutatások körébe. Hazánkban az egészségügyi ellátásban
részesülők központi betegregiszterét az Országos Egészségbiztosítási Pénztár
adatbázisa jelenti. Ide futnak be a hazai fekvő- és járóbeteg-szakellátás havi
adatai, illetve a gyógyszerforgalommal (gyógyszertári receptkiváltással)
kapcsolatos heti jelentések. A retrospektív vizsgálat célja az volt, hogy a
szerzők az Országos Egészségbiztosítási Pénztár adatbázisát közel másfél
évtizedre (2001–2014) visszatekintően diabetológiai szempontból elemezzék, s így
adatokat nyerjenek a cukorbetegséggel kapcsolatos morbiditási és mortalitási
mutatók alakulásáról. Adatokat gyűjtöttek az ellátás költségvonzatáról, a
kórházi kezelés jellemzőiről, illetve a terápiás szokások alakulásáról is. A
jelenlegi dolgozat az elemzés módszertanát tekinti át. A szerzők remélik, hogy
adataik értékesen fogják majd bővíteni a cukorbeteg-ellátás alakulásáról
rendelkezésünkre álló eddigi ismereteket. Orv. Hetil., 2016,
157(32), 1259–1265.
|
Abstract
In the last couple of years, database analyses have become increasingly popular
among clinical-epidemiological investigations. In Hungary, the National Health
Insurance Fund serves as central database of all medical attendances in state
departments and purchases of drug prescriptions in pharmacies. Data from in- and
outpatient departments as well as those from pharmacies are regularly collected
in this database which is public and accessible on request. The aim of this
retrospective study was to investigate the database of the National Health
Insurance Fund in order to analyze the diabetes-associated morbidity and
mortality in the period of years 2001–2014. Moreover, data of therapeutic costs,
features of hospitalizations and practice of antidiabetic treatment were
examined. The authors report now on the method of the database analysis. It is
to be hoped that the upcoming results of this investigation will add some new
data to recent knowledge about diabetes care in Hungary. Orv. Hetil., 2016,
157(32), 1259–1265
Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis
Different Changes of Risks for Stroke and Myocardial Infarction in Patients With Type 2 Diabetes in Hungary Between the Two Periods of 2001–2004 and 2010–2013
Objective: In recent decades several studies reported significant changes in the mortality and morbidity of patients with type 2 diabetes. In this Hungarian nationwide study, we assessed the changes of mortality and cardiovascular risks comparing a group of patient diagnosed during the two periods of 2001–2004 and 2010–2013.Research Design and Methods: We identified patients with type 2 diabetes recorded in the database of the Hungarian National Health Insurance Fund aiming to assess changes of risks for all-cause mortality, myocardial infarction, and stroke during the follow-up periods of 48 months.Results: We included 274,109 patients with newly diagnosed type 2 diabetes between 2001 and 2004, while only 152,678 in the 2010–2013 period. The risk of all-cause mortality at the beginning of the follow-up was not different comparing 2010–2013 to 2001–2004 (HR 1.03), and a mild but significant decrease could be detected (HR 0.87) after 48 months. A lower risk for myocardial infarction was documented in the second month after the diagnosis of diabetes (HR 0.67), which remained constant during the study period and almost the same after 48 months (HR 0.73). On the contrary, our study verified a slightly increased risk for stroke close to the diagnosis [HR 1.06 (1.00–1.13)] and a decreased one [HR 0.72 (0.69–0.79)] at the end of the study.Conclusions: An increased risk for stroke followed by a sharp decrease, and an unchanged risk for myocardial infarction in the Hungarian population with type 2 diabetes possibly resulted in a mild decrease of all-cause mortality between 2001 and 2013
Opposite trends In incidence of breast cancer in young and old female cohorts in Hungary and the impact of the COVID-19 pandemic: a nationwide study between 2011–2020
Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)
BackgroundIn late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered for the vulnerable population starting from August 2021.MethodsThe nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations in the prevention of SARS-CoV-2 infection, Covid-19 related hospitalization and mortality during the Delta wave, compared to an unvaccinated control population without prior SARS-CoV-2 infection.ResultsThe study population included 8,087,988 individuals who were 18–100 years old at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14–120 days after primary immunization in the 16–64 and 65–100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65–100 years, we found high, 88.1%–92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%–95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%–75.3% and 72.9%–100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14–120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster.ConclusionsThe HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave
Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019
Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking.This nationwide, retrospective study examined melanoma survival in Hungary between 2011-2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex, and survival were calculated.Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). 5-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017-2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011-2012 (HR 0.80, 95% CI 0.73-0.89; p<0.0001). Age-standardized 5-year net survival rates in 2011-2014 and 2015-2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0-39 age cohort (94.6% in the 2015-2019 period).Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies
Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary
Objective: While Hungary is often reported to have the highest incidence and mortality rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to confirm these trends. The objective of this study was to estimate the occurrence of lung cancer in Hungary based on a retrospective review of the National Health Insurance Fund (NHIF) database. Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 Jan 2011 and 31 Dec 2016. Age-standardized incidence and mortality rates were calculated using both the 1976 and 2013 European Standard Populations (ESP). Results: Between 2011 and 2016, 6,996 - 7,158 new lung cancer cases were recorded in the NHIF database annually, and 6,045 - 6,465 all-cause deaths occurred per year. Age-adjusted incidence rates were 115.7-101.6/100,000 person-years among men (ESP 1976: 84.7-72.6), showing a mean annual change of - 2.26% (p = 0.008). Incidence rates among women increased from 48.3 to 50.3/100,000 person-years (ESP 1976: 36.9-38.0), corresponding to a mean annual change of 1.23% (p = 0.028). Age-standardized mortality rates varied between 103.8 and 97.2/100,000 person-years (ESP 1976: 72.8-69.7) in men and between 38.3 and 42.7/100,000 person-years (ESP 1976: 27.8-29.3) in women. Conclusion: Age-standardized incidence and mortality rates of lung cancer in Hungary were found to be high compared to Western-European countries, but lower than those reported by previous publications. The incidence of lung cancer decreased in men, while there was an increase in incidence and mortality among female lung cancer patients
Opposite trends in incidence of breast cancer in young and old female cohorts in Hungary and the impact of the Covid-19 pandemic: a nationwide study between 2011–2020
BackgroundThis nationwide study examined breast cancer (BC) incidence and mortality rates in Hungary between 2011–2019, and the impact of the Covid-19 pandemic on the incidence and mortality rates in 2020 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.MethodsOur nationwide, retrospective study included patients who were newly diagnosed with breast cancer (International Codes of Diseases ICD)-10 C50) between Jan 1, 2011 and Dec 31, 2020. Age-standardized incidence and mortality rates (ASRs) were calculated using European Standard Populations (ESP).Results7,729 to 8,233 new breast cancer cases were recorded in the NHIF database annually, and 3,550 to 4,909 all-cause deaths occurred within BC population per year during 2011-2019 period, while 2,096 to 2,223 breast cancer cause-specific death was recorded (CSO). Age-standardized incidence rates varied between 116.73 and 106.16/100,000 PYs, showing a mean annual change of -0.7% (95% CI: -1.21%–0.16%) and a total change of -5.41% (95% CI: -9.24 to -1.32). Age-standardized mortality rates varied between 26.65–24.97/100,000 PYs (mean annual change: -0.58%; 95% CI: -1.31–0.27%; p=0.101; total change: -5.98%; 95% CI: -13.36–2.66). Age-specific incidence rates significantly decreased between 2011 and 2019 in women aged 50–59, 60–69, 80–89, and ≥90 years (-8.22%, -14.28%, -9.14%, and -36.22%, respectively), while it increased in young females by 30.02% (95%CI 17,01%- 51,97%) during the same period. From 2019 to 2020 (in first COVID-19 pandemic year), breast cancer incidence nominally decreased by 12% (incidence rate ratio [RR]: 0.88; 95% CI: 0.69–1.13; 2020 vs. 2019), all-cause mortality nominally increased by 6% (RR: 1.06; 95% CI: 0.79–1.43) among breast cancer patients, and cause-specific mortality did not change (RR: 1.00; 95%CI: 0.86–1.15).ConclusionThe incidence of breast cancer significantly decreased in older age groups (≥50 years), oppositely increased among young females between 2011 and 2019, while cause-specific mortality in breast cancer patients showed a non-significant decrease. In 2020, the Covid-19 pandemic resulted in a nominal, but not statistically significant, 12% decrease in breast cancer incidence, with no significant increase in cause-specific breast cancer mortality observed during 2020
Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016
Objective: No assessment was conducted describing the age and gender specific epidemiology of lung cancer (LC) prior to 2018 in Hungary, thus the objective of this study was to appraise the detailed epidemiology of lung cancer (ICD-10 C34) in Hungary based on a retrospective analysis of the National Health Insurance Fund database. Methods: This longitudinal study included patients aged ≥20 years with LC diagnosis (ICD-10 C34) between January 1, 2011 and December 31, 2016. Patients with different cancer-related codes 6 months before or 12 months after LC diagnosis or having any cancer treatment other than lung cancer protocols were excluded. Results: Lung cancer incidence and mortality increased with age, peaking in the 70–79 age group (375.0/100,000 person-years) among males, while at 60–69 age group for females (148.1/100,000 person-years). The male-to-female incidence rate ratio reached 2.46–3.01 (p 60) annually during the study period. Conclusion: This nationwide epidemiology study demonstrated that LC incidence and mortality in Hungary decreased in younger male and female population, however we found significant increase of incidence in older female population, similar to international trends. Incidence rates peaked in younger age-groups compared to Western countries, most likely due to higher smoking prevalence in these cohorts, while lower age LC incidence could be attributed to higher competing cardiovascular risk resulting in earlier mortality in smoking population